TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02863315

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: tsDCS
Description: Both groups use the same DC-Stimulator Plus (NeuroConn GmbH, Ilmenaus, Germany).~In the tsDCS group, anode electrode is placed over tenth thoracic vertebra to target spinal cord with 2mA for 20 min, and the cathode (reference) electrode on the head vertex (in the Cz location according to the 10-20 EEG system)~In sham tsDCS group, anode electrode is placed over tenth thoracic vertebra to target spinal cord with 2mA for 30s, and the cathode (reference) electrode on the head vertex (in the Cz location according to the 10-20 EEG system). The current was discontinued after 30 s while the power indicator remained on.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: tsDCS
Description: Both groups use the same DC-Stimulator Plus (NeuroConn GmbH, Ilmenaus, Germany).~In the tsDCS group, anode electrode is placed over tenth thoracic vertebra to target spinal cord with 2mA for 20 min, and the cathode (reference) electrode on the head vertex (in the Cz location according to the 10-20 EEG system)~In sham tsDCS group, anode electrode is placed over tenth thoracic vertebra to target spinal cord with 2mA for 30s, and the cathode (reference) electrode on the head vertex (in the Cz location according to the 10-20 EEG system). The current was discontinued after 30 s while the power indicator remained on.
Study: NCT00402246

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Remote Management
Description: The Remote Management method of treating patients consists of 3 components:~CareAlerts: Device alerts that are triggered by either device integrity issues or arrhythmic issues with the patient (e.g. multiple shocks delivered for a ventricular arrhythmia, more than 12 hours of atrial arrhythmias occurring in a day)~Conexus: the device feature which allows the device to wirelessly transmit information (possibly triggered by a CareAlert) to a patient monitor that is hooked up a patient's phone line~CareLink: the Medtronic system which allows device data to be transmitted from a patient's monitor through the phone line to ultimately be displayed on a secure website for viewing by the patient's physician.~The combination of these 3 components allow the patient's device to transmit information relating to either a device issue or patient issue to be viewed by a clinician without the patient having to take direct action.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: In-Office Care
Description: Routine in-office care
Study: NCT02802657

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Conbercept

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Conbercept
Study: NCT00321152

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 6(S)-5-MTHF (a Medical Food)
Description: The study consists of 8 visits over a period of 8 weeks or 60 days. Eligible participants will be randomized to double-blind treatment with placebo or Deplin (6(S)-5-MTHF). Participants will have a greater than 50% chance of receiving active medication (Deplin) at some point in the 8 week study. At the end of the double-blind phase, both responders and non-responders who have completed the 8 week study will have the option of receiving free, open-label adjunctive treatment with either 7.5 mg or 15 mg of 6(S)-5-MTHF for 12 months. Subjects who agree to receive open-label treatment with 6(S)-5-MTHF for 12 months will be assessed every three (3) months until the end of the follow-up phase.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 6(S)-5-MTHF (a Medical Food)
Description: The study consists of 8 visits over a period of 8 weeks or 60 days. Eligible participants will be randomized to double-blind treatment with placebo or Deplin (6(S)-5-MTHF). Participants will have a greater than 50% chance of receiving active medication (Deplin) at some point in the 8 week study. At the end of the double-blind phase, both responders and non-responders who have completed the 8 week study will have the option of receiving free, open-label adjunctive treatment with either 7.5 mg or 15 mg of 6(S)-5-MTHF for 12 months. Subjects who agree to receive open-label treatment with 6(S)-5-MTHF for 12 months will be assessed every three (3) months until the end of the follow-up phase.
Study: NCT01172704

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Skills Building - Motivational Interviewing
Description: SB-MI incorporates Motivational Interviewing strategies into a psycho-educational HIV risk reduction protocol to help participants identify high-risk behaviors, reduce ambivalence about these behaviors, increase motivation to change behaviors, and develop a specific plan of action for risk reduction. Consistent with MI, information gathered at baseline regarding HIV risk behaviors is systematically reviewed in a personalized way with each participant at the outset of the intervention. This is designed to engage participants in becoming active agents in the change process and to assist participants in recognizing discrepancies between their current risk behaviors and goals and values, which typically do not include HIV infection or transmitting HIV to others. Also consistent with the principles of MI, participants are empowered to choose those educational and skills-based modules which fit their personal risk profile and values.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Skills Building - Motivational Interviewing
Description: SB-MI incorporates Motivational Interviewing strategies into a psycho-educational HIV risk reduction protocol to help participants identify high-risk behaviors, reduce ambivalence about these behaviors, increase motivation to change behaviors, and develop a specific plan of action for risk reduction. Consistent with MI, information gathered at baseline regarding HIV risk behaviors is systematically reviewed in a personalized way with each participant at the outset of the intervention. This is designed to engage participants in becoming active agents in the change process and to assist participants in recognizing discrepancies between their current risk behaviors and goals and values, which typically do not include HIV infection or transmitting HIV to others. Also consistent with the principles of MI, participants are empowered to choose those educational and skills-based modules which fit their personal risk profile and values.
Study: NCT00302055

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Clinical referral to diabetes prevention lifestyle
Description: 16 one-hour lifestyle program sessions (diet and physical activity skill building and problem solving) delivered about once weekly over 20-24 weeks, followed by monthly lifestyle maintenance sessions

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Clinical referral to group diabetes prevention lifestyle
Description: 16 one-hour lifestyle program sessions (diet and physical activity skill building and problem solving) delivered about once weekly over 20-24 weeks, followed by monthly lifestyle maintenance sessions
Study: NCT04347434

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atorvastatin 80mg
Description: Atorvastatin is prescribed at a dose of 80 mg / day from the first 24-96 hours of AMI in addition to the standard therapy

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Atorvastatin 80mg
Description: Atorvastatin is prescribed at a dose of 80 mg / day from the first 24-96 hours of AMI in addition to the standard therapy
Study: NCT00321152

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: 6(S)-5-MTHF (a Medical Food)
Description: The study consists of 8 visits over a period of 8 weeks or 60 days. Eligible participants will be randomized to double-blind treatment with placebo or Deplin (6(S)-5-MTHF). Participants will have a greater than 50% chance of receiving active medication (Deplin) at some point in the 8 week study. At the end of the double-blind phase, both responders and non-responders who have completed the 8 week study will have the option of receiving free, open-label adjunctive treatment with either 7.5 mg or 15 mg of 6(S)-5-MTHF for 12 months. Subjects who agree to receive open-label treatment with 6(S)-5-MTHF for 12 months will be assessed every three (3) months until the end of the follow-up phase.
Study: NCT03755752

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Phacoemulsification with and without Trypan Blue capsule staining
Description: Phacoemulsification for patients with diabetic retinopathy having cataract in both eyes. One eye underwent phacoemulsification with trypan blue capsule staining and the other eye underwent phacoemulsification without trypan blue.
Study: NCT04045873

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: extracorporeal membrane oxygenation
Description: The VA-ECMO procedure will be performed by femoral artery access, and the IABP will then be implanted in the contralateral femoral artery.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: extracorporeal membrane oxygenation
Description: The VA-ECMO procedure will be performed by femoral artery access, and the IABP will then be implanted in the contralateral femoral artery.
Study: NCT04102696

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aromatherapy
Description: Free aromatherapy (70% menthol and 30% propanediol) will be provided for 6 months. All participants will receive the standard inhalation method training before hospital discharge.~The aromatherapy will be given twice daily, one treatment in the morning and one in the evening. At each treatment, 4 deep steady inhalations will be performed, and 10 seconds per inhalation is optimal.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Free placebo (10% menthol and 90% propanediol) will be provided for 6 months. The specific method is the same as aromatherapy.
Study: NCT00971191

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-00299804
Description: Brief exposure (5- 11 days) to study drug prior to surgical resection
Study: NCT03003429

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Heart rate monitor
Description: The intervention consist in monitoring the heart rate variability during one night by using a heart rate monitor and a Polar RS800CX
Study: NCT02404909

Intervention type: OTHER
Intervention: IVC diameters evaluation by intraoperative ultrasound
Description: Out of consecutive patients who underwent hepatectomy for primary and secondary liver tumors, patients in whom IVC diameters were intraoperatively measured for clinical reasons were retrospectively selected and analyzed
Study: NCT03307473

Intervention type: BEHAVIORAL
Intervention: E6BIKE
Description: During 3 months in a the geographic area of Clermont-Ferrand (France), new e-bike buyers and renters are invited to take part in VELONAPS study before starting to use their e-bike
Study: NCT04160897

Intervention type: DRUG
Intervention: Tenofovir Disoproxil
Description: tenofovir disopropyl naive for chronic hepatitis B patients
Study: NCT03951402

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 100 mg CG5503 (tapentadol hydrochloride) PR tablet
Description: 100 mg CG5503 (tapentadol hydrochloride) PR tablet.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 100 mg CG5503 (tapentadol hydrochloride) PR tablet
Description: 100 mg CG5503 (tapentadol hydrochloride) PR tablet.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo matching CG5503 PR tablet
Description: Matching placebo tablet to CG5503 PR tablet.
Study: NCT01288443

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alirocumab
Description: Two SC injections in the abdomen only.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alirocumab
Description: Two SC injections in the abdomen only.
Study: NCT02954952

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PSI Rev 1.X
Description: PSI Rev 1.X is an older version of the PSI measurement.

Intervention type: DEVICE
Group type: OTHER
Intervention: PSI Rev 1.X
Description: PSI Rev 1.X is an older version of the PSI measurement.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PSI Rev 2.X
Description: PSI Rev 2.X is a newer version of the PSI measurement.
Study: NCT01288443

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alirocumab
Description: Two SC injections in the abdomen only.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alirocumab
Description: Two SC injections in the abdomen only.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alirocumab
Description: Two SC injections in the abdomen only.
Study: NCT03951402

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo matching CG5503 PR tablet
Description: Matching placebo tablet to CG5503 PR tablet.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo matching CG5503 PR tablet
Description: Matching placebo tablet to CG5503 PR tablet.
Study: NCT03344874

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Stethee®
Description: Stethee® is a new wireless digital stethoscope.
Study: NCT03951402

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo matching moxifloxacin capsule
Description: Matching placebo capsule to moxifloxacin capsule.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo matching moxifloxacin capsule
Description: Matching placebo capsule to moxifloxacin capsule.
Study: NCT01288443

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo (for alirocumab)
Description: Two subcutaneous (SC) injections in the abdomen only.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo (for alirocumab)
Description: Two subcutaneous (SC) injections in the abdomen only.
Study: NCT03344874

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Stethee®
Description: Stethee® is a new wireless digital stethoscope.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: 3MTM Littmann® Classic IIITM
Description: 3MTM Littmann® Classic IIITM is the conventional stethoscope.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 3MTM Littmann® Classic IIITM
Description: 3MTM Littmann® Classic IIITM is the conventional stethoscope.
Study: NCT01288443

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (for alirocumab)
Description: Two subcutaneous (SC) injections in the abdomen only.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atorvastatin
Description: Orally once daily at a stable dose of 10 mg, 20 mg, or 40 mg as background therapy.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atorvastatin
Description: Orally once daily at a stable dose of 10 mg, 20 mg, or 40 mg as background therapy.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atorvastatin
Description: Orally once daily at a stable dose of 10 mg, 20 mg, or 40 mg as background therapy.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atorvastatin
Description: Orally once daily at a stable dose of 10 mg, 20 mg, or 40 mg as background therapy.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atorvastatin
Description: Orally once daily at a stable dose of 10 mg, 20 mg, or 40 mg as background therapy.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Atorvastatin
Description: Orally once daily at a stable dose of 10 mg, 20 mg, or 40 mg as background therapy.
Study: NCT03849014

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Dynamic Hip Screw
Description: Dynamic Hip Screw fixation: Fracture will be reduced under image intensifier. The incision will be made 7-10 cm with a lateral approach. The fascia lata will be incised and the vastus lateralis muscle will be splited along the axis of the femur, without stripping the periosteum. A135° angle guide will be inserted in the lower half of the femoral neck. The barrel of the plate will be guided to the hip screw by direct palpation to minimize the soft-tissue injury. After the insertion of the cortical screw, soft tissue will be protected with 4.5mm drill sleeve during drilling and tapping.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Proximal Femoral Nail
Description: Proximal Femoral Nail fixation: Fracture will be reduced under image intensifier. The incision 2-3 cm with a lateral approach that extended from the cranial part to the tip of the greater trochanter. After palpating the greater trochanter tip, the nail will be then introduced manually into the femoral shaft. The guide wire of the anti-rotational hip blade then introduced. The hip blade should be introduced in the direction of the lower half of the femoral neck. Drilling will be performed under soft-tissue protection with a retractor. The blade will be inserted, and a distal static locking screw and end cap will be inserted under soft tissue protection with a drill sleeve.
Study: NCT04145193

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Standard of Care - mFOLFOX6
Description: Parts of mFOLFOX6 are: Oxaliplatin 85 mg/m2 IV infusion Q2W (Day 1 of every 14-day cycle), Folinic acid (leucovorin) 400 mg/m2 IV infusion Q2W (Day 1 of every 14-day cycle), Fluorouracil (5-FU) 400 mg/m2 IV bolus on Day 1 then 2,400 mg/m2 over 46 to 48 hours IV infusion Q2W (Day 1-2 of every 14-day cycle).

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: E1 - mFOLFOX and durvalumab
Description: Parts of mFOLFOX6 are: Oxaliplatin 85 mg/m2 IV infusion Q2W (Day 1 of every 14-day cycle), Folinic acid (leucovorin) 400 mg/m2 IV infusion Q2W (Day 1 of every 14-day cycle), Fluorouracil (5-FU) 400 mg/m2 IV bolus on Day 1 then 2,400 mg/m2 over 46 to 48 hours IV infusion Q2W (Day 1-2 of every 14-day cycle).~Durvalumab 1500 mg IV, Q4W (Day 1 of every other 14-day cycle)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: E1 - mFOLFOX and durvalumab
Description: Parts of mFOLFOX6 are: Oxaliplatin 85 mg/m2 IV infusion Q2W (Day 1 of every 14-day cycle), Folinic acid (leucovorin) 400 mg/m2 IV infusion Q2W (Day 1 of every 14-day cycle), Fluorouracil (5-FU) 400 mg/m2 IV bolus on Day 1 then 2,400 mg/m2 over 46 to 48 hours IV infusion Q2W (Day 1-2 of every 14-day cycle).~Durvalumab 1500 mg IV, Q4W (Day 1 of every other 14-day cycle)
Study: NCT02261506

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: 7 days of adequate antibiotic treatment durations
Description: We will not be randomizing patients to any specific antibiotic regimen. Patients will be randomized to fixed durations of adequate treatment: 7 versus 14 days. The selection of antibiotic(s) will be at the discretion of the treating team, although the research team will check to ensure that the selected antibiotics have an 'adequate' spectrum of coverage for the bacterial pathogen(s) isolated in the blood culture.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: 14 days of adequate antibiotic treatment durations
Study: NCT01122823

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: chronic disease self-management program (online)
Description: The online CDSMP is an internet-based program for people with 1 or more chronic conditions. It's built on self-efficacy theory, facilitated by lay leaders, and uses a curriculum emphasizing problem solving, decision making, and confidence building in weekly sessions over six weeks. It addresses generic topics and skills relevant to managing any chronic condition, including: action plans; problem solving; nutrition; exercise; fatigue; breathing; managing medications; managing stress and emotions; working with health care providers. The structure includes: 1) password-protected, interactive web-based instruction; 2) web-based bulletin board discussion groups to enable participatory learning and support; 3) and a reference book that contains the program content and supplemental information.
Study: NCT04574141

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: a prolonged release tablet and a spray containing melatonin
Description: prolonged release tablet is dosed at 1.9mg and spray is dosed at 1mg for 2 oral sprays.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: a prolonged release tablet and a spray containing melatonin
Description: prolonged release tablet is dosed at 1.9mg and spray is dosed at 1mg for 2 oral sprays.
Study: NCT04246489

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bintrafusp alfa
Description: Participants received an intravenous infusion of 1200 milligrams (mg) bintrafusp alfa once every 2 weeks until confirmed disease progression, death, unacceptable toxicity and study withdrawal.
Study: NCT03817749

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Exogenous ketone monoester
Description: Participants will consume 20g of the oral ketone monoester supplement 15 minutes prior to each meal of the day for 14 days. All meals will be provided throughout the 14-day supplementation period.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Exogenous ketone monoester
Description: Participants will consume 20g of the oral ketone monoester supplement 15 minutes prior to each meal of the day for 14 days. All meals will be provided throughout the 14-day supplementation period.
Study: NCT01555541

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ofatumumab
Description: 1000 mg IV days 0, 7, 14, 21

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoposide
Description: 10 mg/Kg IV over 24 hours daily, days 1-4

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cytarabine
Description: 2000 mg/m2 IV twice daily, days 1-4